Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Brittney S. Zimmerman,Francisco J. Esteva

DOI: https://doi.org/10.3390/cancers16040800

2024-02-17

Cancers

Abstract:Human epidermal growth factor receptor 2 (HER2) tyrosine kinase is overexpressed in 20% of breast cancers and associated with a less favorable prognosis compared to HER2-negative disease. Patients have traditionally been treated with a combination of chemotherapy and HER2-targeted monoclonal antibodies such as trastuzumab and pertuzumab. The HER2-targeted antibody–drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) represent a novel class of therapeutics in breast cancer. These drugs augment monoclonal antibodies with a cytotoxic payload, which is attached by a linker, forming the basic structure of an ADC. Novel combinations and sequential approaches are under investigation to overcome resistance to T-DM1 and T-DXd. Furthermore, the landscape of HER2-targeted therapy is rapidly advancing with the development of ADCs designed to attack cancer cells with greater precision and reduced toxicity. This review provides an updated summary of the current state of HER2-targeted ADCs as well as a detailed review of investigational agents on the horizon. Clinical trials are crucial in determining the optimal dosing regimens, understanding resistance mechanisms, and identifying patient populations that would derive the most benefit from these treatments. These novel ADCs are at the forefront of a new era in targeted cancer therapy, holding the potential to improve outcomes for patients with HER2-positive and HER2-Low breast cancer.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the drug resistance problem in the treatment of HER2 - positive breast cancer. Specifically, the paper focuses on how to overcome the drug resistance problem in existing treatment regimens and improve the treatment effect by developing a new generation of HER2 - targeted antibody - drug conjugates (ADCs). Currently approved ADCs, such as trastuzumab - mertansine (T - DM1) and trastuzumab - deruxtecan (T - DXd), although they have shown superior effects to traditional treatments in clinical trials, drug resistance remains an unresolved problem. Therefore, this review focuses on the new generation of HER2 - targeted ADCs in the research and development or clinical trial stage, and explores the design features, mechanism of action of these new drugs and their potential in overcoming drug resistance.

The paper also discusses in detail the resistance mechanisms of T - DM1 and T - DXd, including but not limited to antigen - related mechanisms, payload - related mechanisms, endocytosis and intracellular transport pathways, lysosomal dysfunction, drug efflux mechanisms, cell - cycle - dependence, activation of survival signaling pathways and abnormal regulation of apoptosis. In addition, the paper also explores the possibility of overcoming these resistance mechanisms through combination therapies, such as the combined use with monoclonal antibodies, tyrosine kinase inhibitors, PI3K pathway inhibitors, PD1/PDL1 checkpoint inhibitors and CDK4/6 inhibitors.

In summary, this paper aims to provide new ideas and directions for solving the drug resistance problem in the treatment of HER2 - positive breast cancer by introducing the research progress of the new generation of HER2 - targeted ADCs.